Sarcomas - the model for multidisciplinary care in cancer

References

[1] Demetri GD,Blanke CD.Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.N Engl J Med2002;347:472-80

[2] Smith S,Wong L.A consistent chromosome translocation in synovial sarcoma.Cancer Genet Cytogenet1987;26:179-80

[3] Crew AJ,Fisher C.Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma.EMBO J1995;14:2333-40 PMCID:PMC398342

[4] Kadoch C.Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma.Cell2013;153:71-85 PMCID:PMC3655887

[5] McBride MJ,Beird HC.The SS18-SSX fusion oncoprotein hijacks BAF complex targeting and function to drive synovial sarcoma.Cancer Cell2018;33:1128-41.e7 PMCID:PMC6791822

[6] Antonescu CR,Zhang L.Sarcomas With CIC-rearrangements are a distinct pathologic entity with aggressive outcome: a clinicopathologic and molecular study of 115 cases.Am J Surg Pathol2017;41:941-9 PMCID:PMC5468475

[7] Schöffski P,Gelderblom H.Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial.Lancet Respir Med2018;6:431-41

[8] Gounder M,Jones RL.Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study.Lancet Oncol2020;21:1423-32

[9] Karolak M,Shipley J.Targeting EZH2 for the treatment of soft tissue sarcomas.J Cancer Metastasis Treat2021;7:15

[10] Abe K,Domoto T.Glycogen synthase kinase 3ß biology in bone and soft tissue sarcomas.J Cancer Metastasis Treat2020;6:51

[11] Walz A,Chandra S.Molecular pathways: revisiting glycogen synthase kinase-3beta as a target for the treatment of cancer.Clin Cancer Res2017;23:1891-7 PMCID:PMC5392367

[12] Shimozaki S,Domoto T.Efficacy of glycogen synthase kinase-3beta targeting against osteosarcoma via activation of beta-catenin.Oncotarget2016;7:77038-51 PMCID:PMC5363568

[13] Abe K,Domoto T.Glycogen synthase kinase 3beta as a potential therapeutic target in synovial sarcoma and fibrosarcoma.Cancer Sci2020;111:429-40 PMCID:PMC7004542

[14] Tran DTP,Pongsuchart M.ROR2 regulates the survival of murine osteosarcoma cells in lung capillaries.J Cancer Metastasis Treat2020;6:47

[15] Pacheco M.Primary malignant tumors of bone surface: a review with emphasis on differential diagnosis.J Cancer Metastasis Treat2020;6:49

[16] Pinanamaneni S.Proximal humerus reconstruction in orthopaedic oncology.J Cancer Metastasis Treat2021;7:7

[17] Baker LH,Reinke DK.Burden of chronic diseases among sarcoma survivors treated with anthracycline chemotherapy: results from an observational study.J Cancer Metastasis Treat2020;6:24

[18] Gronchi A,Quagliuolo V.Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.Lancet Oncol2017;18:812-22

[19] Lipshultz SE,Lipsitz SR.Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.Lancet Oncol2010;11:950-61 PMCID:PMC3756093

[20] Kopp LM,Schwartz CL.Effects of dexrazoxane on doxorubicin-related cardiotoxicity and second malignant neoplasms in children with osteosarcoma: a report from the Children's Oncology Group.Cardiooncology2019;5:15 PMCID:PMC7048050